Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma

Heather A. Personett, Erin F. Barreto, Kristen B. McCullough, Ross Dierkhising, Nelson Leung, Thomas Matthew Habermann

Research output: Contribution to journalArticle

Abstract

Early administration of rasburicase to enhance uric acid (UA) elimination has been adopted without robust evidence in support of its impact on clinical outcomes in tumor lysis syndrome (TLS), specifically, the prevention of acute kidney injury (AKI). This was a retrospective cohort study of adult lymphoma patients at intermediate or high risk for TLS. Excluded patients had AKI or were on dialysis at hospital admission. The incidence of new AKI in the setting of TLS was described along with predictors of its development, including early rasburicase use. In 383 included patients, the incidence of new-onset AKI during hospitalization was 6%. Predictors included age, history of renal or cardiovascular disease, and UA >8 mg/dL. Rasburicase use did not significantly impact the risk of developing AKI (HR 2.3; p =.11). The UA level at the time of administration did not modify the effect of rasburicase on prevention of AKI (p =.36 for the interaction term).

Original languageEnglish (US)
JournalLeukemia and Lymphoma
DOIs
StatePublished - Jan 1 2019

Fingerprint

Tumor Lysis Syndrome
Acute Kidney Injury
Lymphoma
Incidence
Uric Acid
rasburicase
Dialysis
Hospitalization
Cohort Studies
Cardiovascular Diseases
Retrospective Studies
Kidney

Keywords

  • acute kidney injury
  • lymphoid leukemia
  • Lymphoma and Hodgkin disease
  • pharmacotherapeutics
  • rasburicase
  • tumor lysis syndrome

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma. / Personett, Heather A.; Barreto, Erin F.; McCullough, Kristen B.; Dierkhising, Ross; Leung, Nelson; Habermann, Thomas Matthew.

In: Leukemia and Lymphoma, 01.01.2019.

Research output: Contribution to journalArticle

Personett, Heather A. ; Barreto, Erin F. ; McCullough, Kristen B. ; Dierkhising, Ross ; Leung, Nelson ; Habermann, Thomas Matthew. / Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma. In: Leukemia and Lymphoma. 2019.
@article{dd710fa0c2e84bc2a86c78e64c4262fe,
title = "Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma",
abstract = "Early administration of rasburicase to enhance uric acid (UA) elimination has been adopted without robust evidence in support of its impact on clinical outcomes in tumor lysis syndrome (TLS), specifically, the prevention of acute kidney injury (AKI). This was a retrospective cohort study of adult lymphoma patients at intermediate or high risk for TLS. Excluded patients had AKI or were on dialysis at hospital admission. The incidence of new AKI in the setting of TLS was described along with predictors of its development, including early rasburicase use. In 383 included patients, the incidence of new-onset AKI during hospitalization was 6{\%}. Predictors included age, history of renal or cardiovascular disease, and UA >8 mg/dL. Rasburicase use did not significantly impact the risk of developing AKI (HR 2.3; p =.11). The UA level at the time of administration did not modify the effect of rasburicase on prevention of AKI (p =.36 for the interaction term).",
keywords = "acute kidney injury, lymphoid leukemia, Lymphoma and Hodgkin disease, pharmacotherapeutics, rasburicase, tumor lysis syndrome",
author = "Personett, {Heather A.} and Barreto, {Erin F.} and McCullough, {Kristen B.} and Ross Dierkhising and Nelson Leung and Habermann, {Thomas Matthew}",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/10428194.2019.1574000",
language = "English (US)",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma

AU - Personett, Heather A.

AU - Barreto, Erin F.

AU - McCullough, Kristen B.

AU - Dierkhising, Ross

AU - Leung, Nelson

AU - Habermann, Thomas Matthew

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Early administration of rasburicase to enhance uric acid (UA) elimination has been adopted without robust evidence in support of its impact on clinical outcomes in tumor lysis syndrome (TLS), specifically, the prevention of acute kidney injury (AKI). This was a retrospective cohort study of adult lymphoma patients at intermediate or high risk for TLS. Excluded patients had AKI or were on dialysis at hospital admission. The incidence of new AKI in the setting of TLS was described along with predictors of its development, including early rasburicase use. In 383 included patients, the incidence of new-onset AKI during hospitalization was 6%. Predictors included age, history of renal or cardiovascular disease, and UA >8 mg/dL. Rasburicase use did not significantly impact the risk of developing AKI (HR 2.3; p =.11). The UA level at the time of administration did not modify the effect of rasburicase on prevention of AKI (p =.36 for the interaction term).

AB - Early administration of rasburicase to enhance uric acid (UA) elimination has been adopted without robust evidence in support of its impact on clinical outcomes in tumor lysis syndrome (TLS), specifically, the prevention of acute kidney injury (AKI). This was a retrospective cohort study of adult lymphoma patients at intermediate or high risk for TLS. Excluded patients had AKI or were on dialysis at hospital admission. The incidence of new AKI in the setting of TLS was described along with predictors of its development, including early rasburicase use. In 383 included patients, the incidence of new-onset AKI during hospitalization was 6%. Predictors included age, history of renal or cardiovascular disease, and UA >8 mg/dL. Rasburicase use did not significantly impact the risk of developing AKI (HR 2.3; p =.11). The UA level at the time of administration did not modify the effect of rasburicase on prevention of AKI (p =.36 for the interaction term).

KW - acute kidney injury

KW - lymphoid leukemia

KW - Lymphoma and Hodgkin disease

KW - pharmacotherapeutics

KW - rasburicase

KW - tumor lysis syndrome

UR - http://www.scopus.com/inward/record.url?scp=85067866930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067866930&partnerID=8YFLogxK

U2 - 10.1080/10428194.2019.1574000

DO - 10.1080/10428194.2019.1574000

M3 - Article

C2 - 31223041

AN - SCOPUS:85067866930

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -